• 1
    Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza – United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; 59:10571062.
  • 2
    Pitman RJ, Melegaro A, Gelb D, Siddiqui MR, Gay NJ, Edmunds WJ. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 2007; 54:530538.
  • 3
    Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:13331340.
  • 4
    Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:3644.
  • 5
    Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010; 2:CD004876.
  • 6
    Langley JM, Risi G, Caldwell M et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 2011; 203:17291738.
  • 7
    Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580589.
  • 8
    Heijmans S, De Meulemeester M, Reynders P et al. Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 2011; 203:10541062.
  • 9
    Lasko B, Reich D, Madan A, Roman F, Li P, Vaughn D. Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults. J Infect Dis 2011; 204:574581.
  • 10
    Nicholson KG, Abrams KR, Batham S et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011; 11:91101.
  • 11
    Van Buynder PG, Konrad S, Van Buynder JL et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 2013; 31:61226128.
  • 12
    Food and Drug Administration. Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available at (Accessed 7 February 2013).
  • 13
    Osborne RH, Norquist JM, Elsworth GR et al. Development and validation of the Influenza Intensity and Impact Questionnaire (FluiiQ™). Value Health 2011; 14:687699.
  • 14
    McElhaney JE, Beran J, Devaster J-M et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013; 13:485496.
  • 15
    Vesikari T, Beran J, Durviaux S et al. Use of real-time polymerase chain reaction (rtPCR) as a diagnostic tool for influenza infection in a vaccine efficacy trial. J Clin Virol 2012; 53:2228.
  • 16
    Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc Series B Stat Methodol 1977; 39:138.
  • 17
    Schafer JL. Analysis of incomplete multivariate data, Monographs on Statistics and Applied Probability 72. London: Chapman & Hall, 1997.
  • 18
    Wyrwich KW, Norquist JM, Lenderking WR, Acaster S. Methods for interpreting change over time in patient-reported outcome measures. Qual Life Res 2013; 22:475483.
  • 19
    Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006; 4:70.
  • 20
    Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR; Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77:371383.
  • 21
    Center for Infectious Disease Research and Policy (CIDRAP). The compelling need for game-changing influenza vaccines. An analysis of the influenza vaccine enterprise and recommendations for the future. October 2012. Available at (Accessed 20 November 2012).
  • 22
    Gill TM, Allore HG, Holford TR, Guo Z. Hospitalization, restricted activity, and the development of disability among older persons. JAMA 2004; 292:21152124.
  • 23
    McElhaney JE, Xie D, Hager WD et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006; 176:63336339.